Go To Main content
Unit_Image
:::

::: Faculty of GILS

蔡易達 Lecture

蔡易達 Lecture      
Yi-Ta Tsai

Position

Lecture

Office Phone

02-87923100 ext.19391

E-mail

feg81230@gmail.com

Education

Ph.D. ,Graduate Institute of Medical Sciences, National Defense Medical Center, ROC

Professional Experiences

1.Sep. 2022-present Assistant Professor, Graduate Institute of Life Sciences,
National Defense Medical Center, Taipei, Taiwan
2. Feb. 2018- Aug. 2022 Postdoctoral Fellow/ National Defense Medical Center , Taipei, Taiwan

Research Interests

Cancer Biology, Cell and Molecular Biology, Signals from the tumor microenvironment.

Recent Publications

1. Chien-Chang Kao, Ching-Liang Ho, Ming-Hsin Yang, Yi-Ta Tsai , Shu-Yu Liu, Ping-Ying Chang, Yi-Ying Wu, Jia-Hong Chen, Tzu-Chuan Huang, Ren-Hua Yehn, Ming-Shen Dai, Yeu-Chin Chen, Guang-Huan Sun, Tai-Lung Cha (2022).
Phase I Targeted Combination Trial of Sorafenib and GW5074 in Patients with Advanced Refractory Solid Tumors. journal of clinical medicine, 2022 Apr 14;11(8):2183.

2. Pei-Jhang Chiang, Ting Xu, Tai-Lung Cha, Yi-Ta Tsai , Shu-Yu Liu, Sheng-Tang Wu, En Meng, Chih-Wei Tsao , Chien-Chang Kao, Chin-Li Chen, Guang-Huan Sun, Dah-Shyong Yu, Sun-Yran Chang, Ming-Hsin Yang (2021, Jul).
Programmed Cell Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor of Treatment Response in Patients with Urothelial Carcinoma. Biology (Basel), 2021 Jul 16;10(7):674.

3. Kao-Hui Liu, Yi-Ta Tsai, Szu-Ying Chin, Woan-Ruoh Lee, Yen-Chou Chen, Shing-Chuan Shen (2018, Nov). Hypoxia Stimulates the Epithelial-toMesenchymal Transition in Lung Cancer Cells Through Accumulation of Nuclear β-Catenin. anticancer research.

4. Tsung-Yun Hou, Ming-Rong Chen, Yu-Ching Chou, Po-Chieh Kan , Yi-Ta Tsai, Tai-Lung Cha (2017, Jul). Impact of Enhancer of Zeste Homolog 2 on T Helper Cell-Mediated Allergic Rhinitis. Frontiers in Immunology , 2017 Jul 10;8:790.

5. Xiang-Me Lai, Shu-Yu Liu, Yi-Ta Tsai, Guang-Huan Sun, Sun-Yran Chang, Shih-Ming Huang, Tai-Lung Cha (2017, Jul). HAF mediates the evasive resistance of anti-angiogenesis TKI through disrupting HIF-1α and HIF-2α
balance in renal cell carcinoma. Oncotarget, 2017 Jul 25;8(30):49713-49724 Patents
PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING CANCER AND BIOMARKERS FOR DRUG SCREENING;Cha Tai-Lung , Chang Sun-Yran , Sun Guang-Huan , Lin Chung-Chih , Tsai Yi-Ta;US9,782,393(B2);USA

    Views:149
  • Update Date:2022-09-22